Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jörg T Hartmann

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Anti-Cancer Drugs|February 1, 2007
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclinesJörg T Hartmann
Onkologie|September 17, 2011
[Solid tumors in young patients]Jörg T Hartmann, Anja Lorch
Drug Safety|March 10, 2006
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profileJörg T Hartmann, Hans-Peter Lipp
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
Skin toxicity of anti-cancer therapyJens Ulrich, Jörg T Hartmann, Wolfgang Dörr, et al.
Clinical & Experimental Metastasis|February 26, 2010
Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancerTina Wiesner, Stefanie Bugl, Frank Mayer, et al.
Onkologie|January 5, 2007
Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasoneKarin Oechsle, Martin R Müller, Jörg T Hartmann, et al.
Investigational New Drugs|May 4, 2005
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell linesFrank Mayer, Sandra Mueller, Elke Malenke, et al.
MMW Fortschritte Der Medizin|January 15, 2011
[Side effect of oncological treatment in skin and adnexae]Julia Haagen, Jörg T Hartmann, Margret Schmidt, et al.
Journal of Cancer Research and Clinical Oncology|August 15, 2009
Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysisJohannes Classen, Rainer Souchon, Thomas Hehr, et al.
Haematologica|December 30, 2006
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphomaJörg T Hartmann, Ines Meisinger, Stefan M Kröber, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Anti-Cancer Drugs|February 1, 2007
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclinesJörg T Hartmann
Onkologie|September 17, 2011
[Solid tumors in young patients]Jörg T Hartmann, Anja Lorch
Drug Safety|March 10, 2006
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profileJörg T Hartmann, Hans-Peter Lipp
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
Skin toxicity of anti-cancer therapyJens Ulrich, Jörg T Hartmann, Wolfgang Dörr, et al.
Clinical & Experimental Metastasis|February 26, 2010
Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancerTina Wiesner, Stefanie Bugl, Frank Mayer, et al.
Onkologie|January 5, 2007
Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasoneKarin Oechsle, Martin R Müller, Jörg T Hartmann, et al.
Investigational New Drugs|May 4, 2005
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell linesFrank Mayer, Sandra Mueller, Elke Malenke, et al.
MMW Fortschritte Der Medizin|January 15, 2011
[Side effect of oncological treatment in skin and adnexae]Julia Haagen, Jörg T Hartmann, Margret Schmidt, et al.
Journal of Cancer Research and Clinical Oncology|August 15, 2009
Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysisJohannes Classen, Rainer Souchon, Thomas Hehr, et al.
Haematologica|December 30, 2006
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphomaJörg T Hartmann, Ines Meisinger, Stefan M Kröber, et al.
Pageof 4